Dashboard
Manage Tickers

ASMB ASSEMBLY BIOSCIENCES, INC.

Nasdaq assemblybio.com


$ 33.00 $ 1.06 (3.31 %)    

Tuesday, 11-Nov-2025 16:58:07 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 625.49 $ 0.00 (0 %)
DIA $ 480.57 $ 0.00 (0 %)
SPY $ 685.40 $ 0.00 (0 %)
TLT $ 89.92 $ 0.00 (0 %)
GLD $ 379.59 $ 0.00 (0 %)
$ 33.13
$ 32.11
$ 32.05 x 100
$ 34.00 x 375
-- - --
$ 7.75 - $ 33.26
65,290
na
524.02M
$ 1.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-10-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-20-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 03-28-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 03-22-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-11-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-05-2020 06-30-2020 10-Q
23 05-08-2020 03-31-2020 10-Q
24 03-04-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-05-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 02-28-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-08-2018 06-30-2018 10-Q
31 05-07-2018 03-31-2018 10-Q
32 03-08-2018 12-31-2017 10-K
33 11-01-2017 09-30-2017 10-Q
34 08-09-2017 06-30-2017 10-Q
35 05-08-2017 03-31-2017 10-Q
36 03-02-2017 12-31-2016 10-K
37 11-09-2016 09-30-2016 10-Q
38 08-09-2016 06-30-2016 10-Q
39 05-10-2016 03-31-2016 10-Q
40 03-11-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

assembly-biosciences-q3-eps-072-beats-078-estimate-sales-10789m-beat-7459m-estimate
Assembly Biosciences Q3 EPS $(0.72) Beats ...
11/10/2025 21:41:20

Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of ...

assembly-biosciences-data-from-phase-1b-study-demonstrates-abi-4334-was-well-tolerated-across-both-dose-levels-in-patients-with-chronic-hepatitis-b
Assembly Biosciences Data From Phase 1b St...
11/07/2025 13:09:31

Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral d...

forecasting-the-future-4-analyst-projections-for-assembly-biosciences
Forecasting The Future: 4 Analyst Projecti...
10/14/2025 21:01:31

assembly-biosciences-files-prospectus-relates-to-offering-resale-from-time-to-time-of-up-to-698m-shares-by-selling-stockholder
Assembly Biosciences Files Prospectus Rela...
10/14/2025 20:24:26

- SEC Filing

hc-wainwright--co-reiterates-buy-on-assembly-biosciences-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Asse...
10/14/2025 11:17:34

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $...

assembly-biosciences-highlights-interim-phase-1b-clinical-data-for-long-acting-hsv-helicase-primase-inhibitor-candidate-abi-5366-in-late-breaking-oral-presentation-at-congress-of-iusti--europe
Assembly Biosciences Highlights Interim Ph...
10/10/2025 12:09:45

4-biotechnology-stocks-that-outshine-in-momentum-amid-strong-technicals
4 Biotechnology Stocks That Outshine In Mo...
09/29/2025 11:11:04

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week ...

jmp-securities-initiates-coverage-on-assembly-biosciences-with-market-outperform-rating-announces-price-target-of-38
JMP Securities Initiates Coverage On Assem...
09/24/2025 13:00:37

JMP Securities analyst Roy Buchanan initiates coverage on Assembly Biosciences (NASDAQ:ASMB) with a Market Outperform rating...

guggenheim-maintains-buy-on-assembly-biosciences-raises-price-target-to-39
Guggenheim Maintains Buy on Assembly Biosc...
09/08/2025 13:38:24

Guggenheim analyst Vamil Divan maintains Assembly Biosciences (NASDAQ:ASMB) with a Buy and raises the price target from $31 ...

hc-wainwright--co-assumes-assembly-biosciences-at-buy-announces-price-target-of-50
HC Wainwright & Co. Assumes Assembly Biosc...
08/18/2025 10:40:52

HC Wainwright & Co. analyst Patrick Trucchio assumes Assembly Biosciences (NASDAQ:ASMB) with a Buy rating and announces ...

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
08/08/2025 21:08:06

assembly-biosciences-reports-interim-results-from-phase-1b-clinical-study-of-abi-5366-showing-94-reduction-in-hsv-2-shedding-rate-and-98-reduction-in-high-viral-load-shedding-rate
Assembly Biosciences Reports Interim Resul...
08/08/2025 12:09:44

assembly-biosciences-cash-cash-equivalents-and-marketable-securities-were-75m-projected-to-fund-operations-into-mid-2026
Assembly Biosciences' Cash, Cash Equivalen...
08/06/2025 21:08:20

assembly-biosciences-q2-2025-eps-133-beats-136-estimate-sales-9626m-beat-6262m-estimate
Assembly Biosciences Q2 2025 EPS $(1.33) B...
08/06/2025 21:07:32

assembly-biosciences-announced-interim-data-from-several-cohorts-from-the-ongoing-phase-1a-trial-of-abi-6250-for-hepatitis-delta-virus
Assembly Biosciences Announced Interim Dat...
08/06/2025 21:05:55

Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-62...

reported-saturday-assembly-biosciences-presents-phase-1a-and-preclinical-data-for-abi-5366-and-abi-1179-herpes-candidates-at-sti--hiv-2025-and-international-herpesvirus-workshop
Reported Saturday, Assembly Biosciences Pr...
07/28/2025 06:23:26

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex vir...

assembly-biosciences-announces-topline-results-from-its-phase-1b-clinical-trial-of-next-generation-investigational-capsid-assembly-modulator-abi-4334-in-chronic-hepatitis-b
Assembly Biosciences Announces Topline Res...
06/25/2025 12:02:15

– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be obs...

syndeio-biosciences-launches-to-pioneer-precision-neurotherapeutics-focused-on-repairing-and-enhancing-synaptic-function-in-central-nervous-system-diseases
Syndeio Biosciences Launches To Pioneer Pr...
05/27/2025 11:07:36

Clinical portfolio, informed by deep and novel synapse biology and pharmacology insights, aims to strengthen neural connections...

assembly-biosciences-q1-eps-117-beats-160-estimate-sales-942m-beat-763m-estimate
Assembly Biosciences Q1 EPS $(1.17) Beats ...
05/08/2025 20:52:27

Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimate of ...

assembly-biosciences-releases-new-preclinical-date-for-oral-hepatitis-d-virus-entry-inhibitor-abi-6250-and-next-generation-hepatitis-b-virus-capsid-assembly-modulator-abi-4334-at-the-easl-congress-2025-in-amsterdam
Assembly Biosciences Releases New Preclini...
05/07/2025 12:09:44

– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 –– Sec...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION